Across TCGA pan-cancer cohorts, S100A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated S100A2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher S100A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated S100A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where S100A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.373	0.654	.001	60	view →
CCRCC	DFS	Quartile	III,IV	0.741	1.000	.029	3	view →
HNSC	DFS	Quartile	II,III,IV	0.982	0.854	.037	2	view →
LUAD	OS	Median	II,III,IV	0.467	0.907	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: S100A2 tumor-vs-normal RNA expression · all S100A2 data types